NCT04665687Recruiting
Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients
Clinical Sequencing Project for Early Gastric Cancer and Precancerous Gastric Adenoma Patients for Personalized Cancer Clinic
Source: ClinicalTrials.gov · Last updated 12 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence. Liquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1730 (estimated)
- First submitted
- 8 Nov 2020
- Start date
- 17 Dec 2020
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Samsung Medical Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04665687
What you commit to
- Study type: Observational
- Planned participants: 1730
- From 17 Dec 2020 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Those who will not yield enough samples
- Those who are considered inappropriate for this study in the discretion of the researchers
Who the study is looking for
- Those who are over the age of 19
- Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma
- Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy/endodoscopic removal for treatment and diagnosis
- Those whose life expectancy is more than 3 months
- Those who have voluntarily consented to participate in this clinical trial
Age in the registry: 19 years to 100 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.